Engelmann's disease (progressive diaphyseal dysplasia) is commonly regarded as a metabolic disease of bone and has been described in over 100 patients.1
The features of painful cortical thickening and sclerosis of diaphyses with muscular wasting and weakness are characteristic. Its autosomal dominant inheritance has been emphasised, though sporadic cases are recorded. Smith et al.2 highlighted the inconstant biochemical changes of raised serum alkaline phosphatase and urinary total hydroxyproline and, occasionally, hypocalcaemia, hyperphosphataemia, and positive calcium balance. Much less attention has been paid to other associated systemic features including anaemia, leucopenia, hepatosplenomegaly, raised erythrocyte sedimentation rate (ESR), and the striking improvement obtained with corticosteroid therapy.3 This paper describes a patient with Engelmann's rheumatoid and antinuclear factor tests were negative. An 52Fe scan showed a normal distribution of iron with no evidence of extramedullary haemopoiesis, thus excluding significant bony encroachment on marrow cavities typical of osteopetrosis (Fig. 5) . The 1972 emphasise the wide range of severity, and it is possible that many cases are diagnosed as Paget's disease to which it has a superficial resemblance in visual appearance, warmth overlying affected bones, and raised alkaline phosphatase. However, the autosomal dominant inheritance, the age of onset in childhood or adolescence, and the proximal myopathy all serve to distinguish it.
The systemic features described in our patient are not a chance finding. Lennon The abrupt response to corticosteroid therapy is perhaps the primary feature that removes Engelmann's disease from the spectrum of purely 'metabolic bone diseases.' Allen et al.3 described the clinical improvement with steroids in 3 patients and histologically confirmed increased bone resorption and secondary remodelling, with increased osteoclastic activity and decreased lamellar bone deposition. The mode of action of corticosteroids on the bone pathophysiology is obscure. They may suppress periosteal overactivity, which presumably leads to the excessive bone deposition. What vascular, immunological, or other fundamental defects trigger this overactivity is unknown.
It is acknowledged that the autosomal dominant inheritance of Engelmann' s disease may just include an increased predisposition to a connective tissue disease. At least there is much evidence to conclude that it is more than a rare locomotor syndrome confined to bone and muscle. No previous record of HLA typing in Engelmann's disease is available, and further reports are awaited. Although the ANF was weakly positive, no evidence of complement consumption or of immune complexes was found. However, these tests were performed during clinical and haematological remission on steroid therapy and should be performed in other untreated cases.
